Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Major Depressive Disorder Clinical Trial

Official title: Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram is effective in treatment of moderate to severe depression

Clinical Trial Description

Pioglitazone as a Ppar-gamma agonist is an anti diabetic drug. It was also shown that, it has certain anti inflammatory and neuro-protective effects. In recent years it has been proposed that Ppar-gamma agonists may have effects on mood and cognition. In animal studies and in one human case report as well as a pilot study on human subjects these drugs improved symptoms of depression. A randomized controlled and double blind design will provide further evidence for the efficacy of these drugs in major depressive disorder. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

• NCT number: NCT01109030
• Study type: Interventional
• Source: Tehran University of Medical Sciences
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: April 2010
• Completion date: October 2011